Bisphosphonate Duplex Drugs for Bone-Targeted Antitumor Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a continuous need for targeted treatments for bone-related disorders such as bone tumors or metastatic bone tumors, as existing therapies lack effective bone-targeting mechanisms.
Innovation Solution
Development of pyrimidine compounds specifically derivatized with bisphosphonates, where aminobisphosphonates like alendronate and pamidronate are covalently linked with chemotherapeutic nucleoside analogues like 5-FdU, AZT, and araC, creating bisphosphonate duplex drugs that enable bone-targeting through their bisphosphonate residue, potentially producing cytostatic active compounds with additive or synergistic antitumor effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapeutic drugs are used, then antitumor activity is achieved, but bone-targeting capability is lost
Solution Approach 1:
The patent combines two distinct functional components into a single duplex drug molecule: a chemotherapeutic agent (5-FdU, AZT, or araC) and a bone-targeting bisphosphonate (alendronate or pamidronate). This merging allows the drug to simultaneously achieve antitumor activity through the chemotherapeutic component and bone-targeting capability through the bisphosphonate component, resolving the contradiction between these two functions.
Solution Approach 2:
The invention creates a composite molecular structure where a nucleoside analogue is covalently linked to an aminobisphosphonate. This composite structure integrates the pharmacological properties of both components: the antitumor activity of the nucleoside analogue and the bone-affinity of the bisphosphonate, enabling the drug to function as both a chemotherapeutic agent and a bone-targeting vector.
2Adaptability or versatility
If bone-targeting bisphosphonates are used, then bone-targeting capability is achieved, but direct antitumor activity is reduced
Solution Approach 1:
The duplex drug structure merges the bone-targeting bisphosphonate with a chemotherapeutic nucleoside analogue, ensuring that both functions are present in a single molecule. The chemotherapeutic component restores the direct antitumor activity that would be lost if only the bisphosphonate were used, while the bisphosphonate ensures bone-targeting capability.
Solution Approach 2:
The bisphosphonate portion of the duplex drug serves multiple functions: it provides bone-targeting capability by binding to hydroxylapatite in bone tissue, and it also contributes to antitumor activity as bisphosphonates have direct cytostatic effects on tumor cells. This multi-functionality helps compensate for any reduction in antitumor activity.
3Reliability
If duplex drugs are synthesized, then bone-targeted therapy with additive or synergistic effects is achieved, but manufacturing complexity increases
Solution Approach 1:
The synthesis is divided into distinct segments or steps: first, the nucleoside analogue is triazolylated at the 4-position; second, the aminobisphosphonate is coupled to the triazolylated intermediate; and third, deprotection is performed. This segmentation of the synthesis process makes the complex duplex drug manufacturing more manageable and systematic.
Solution Approach 2:
The triazolyl group serves as an intermediary or mediator in the synthesis. It is introduced onto the nucleoside analogue first, providing a reactive handle for subsequent coupling with the aminobisphosphonate. This intermediary approach simplifies the overall synthesis by creating a modular assembly process rather than requiring direct coupling of the final components.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The bisphosphonate duplex drugs demonstrate variable growth inhibition of tumor cell lines, offering a new approach for bone-targeted therapy with potential for enhanced antitumor activity and bone health applications.
Implementation Method 1
The powerful binding affinity towards bones is used in medicine for treatment in bone resorption and other bone disorders
Implementation Method 2
The P—C—P bond is relatively stable towards chemicals and enzymatic hydrolysis
Data Source
AI summary
The present invention relates to novel bisphosphonate duplex drugs, methods for preparing said compound; pharmaceutical compositions containing the same; as well as the use of said compounds in human and veterinary medicine, and, in particular, for treating tumors, viral infections; or dental disorders.